AFMD - Affimed N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.575
-0.025 (-1.56%)
As of 10:28AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.600
Open1.550
Bid1.550 x 2200
Ask1.600 x 1000
Day's Range1.550 - 1.600
52 Week Range1.150 - 2.850
Volume110,536
Avg. Volume390,765
Market Cap98.264M
Beta2.50
PE Ratio (TTM)N/A
EPS (TTM)-0.757
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.65
Trade prices are not sourced from all markets
  • Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates
    Zacks12 days ago

    Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates

    Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 5.88% and -70.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire12 days ago

    Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress

    Heidelberg, Germany, August 8, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate ...

  • ACCESSWIRE12 days ago

    Affimed N.V. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To listen ...

  • GlobeNewswire17 days ago

    Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

    Heidelberg, Germany, August 3, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on August ...

  • ACCESSWIRE25 days ago

    Free Technical Research on Advaxis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on ADXS sign up now at www.wallstequities.com/registration. On Wednesday, July 25, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories.

  • Implied Volatility Surging for Affimed (AFMD) Stock Options
    Zackslast month

    Implied Volatility Surging for Affimed (AFMD) Stock Options

    Affimed (AFMD) needs investors to pay close attention to the stock based on moves in the options market lately.

  • GlobeNewswire2 months ago

    MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens

    MolMed S.p.A. (MLMD.MI), a medical biotechnology company focusing on research, development, manufacturing, and clinical validation of cell & gene therapies to treat cancer and rare diseases and AbCheck s.r.o., a technology company focusing on the discovery and optimization of high-quality human antibodies, today announced that they have entered into a three-year Master Agreement aimed at providing MolMed with selected and optimized antibodies for the development of new Chimeric Antigen Receptors (CARs), targeting both liquid and solid tumors. Under the agreement, AbCheck will use its proprietary discovery platform to select, optimize and deliver multiple human single-chain variable fragments (scFvs), specifically recognizing each MolMed target candidate.

  • Benzinga2 months ago

    Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data

    Affimed NV (NASDAQ: AFMD ) shares were tumbling Friday after the release of updated data on its Hodgkin lymphoma treatment candidate. The metric investors are reacting to may be a decline in complete metabolic ...

  • GlobeNewswire2 months ago

    Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

    Affimed N.V. (AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today presented new interim data from the Phase 1b dose escalation study evaluating AFM13, its lead NK cell engager candidate, at the European Hematology Association (EHA) 23rd Congress in Stockholm. Dr. Eva Domingo of the Instituto Catalán de Oncología L'Hospitalet, Barcelona, Spain, presented the poster, titled A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data.

  • SmarterAnalyst2 months ago

    3 Biotechs with Upcoming Data to Watch

    Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.

  • ACCESSWIRE2 months ago

    Today’s Free Research Reports Coverage on Agenus and Three More Biotech Stocks

    In today's pre-market research, WallStEquities.com evaluates Affimed N.V. (NASDAQ: AFMD), Agenus Inc. (NASDAQ: AGEN), Akcea Therapeutics Inc. (AKCA), and Akebia Therapeutics Inc. (NASDAQ: AKBA). The Company's shares are trading 8.38% above their 200-day moving average.

  • GlobeNewswire3 months ago

    Affimed to Present at the Jefferies Global Healthcare Conference

    Heidelberg, Germany, May 30, 2018- Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AFMD earnings conference call or presentation 15-May-18 12:30pm GMT

    Q1 2018 Affimed NV Earnings Call

  • Does Affimed NV. (NASDAQ:AFMD) Fall With The Market?
    Simply Wall St.3 months ago

    Does Affimed NV. (NASDAQ:AFMD) Fall With The Market?

    If you are looking to invest in Affimed NV.’s (NASDAQ:AFMD), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • ACCESSWIRE3 months ago

    Affimed N.V. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time. To listen ...

  • ACCESSWIRE4 months ago

    Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy

    LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of AFMD earnings conference call or presentation 20-Mar-18 12:30pm GMT

    Q4 2017 Affimed NV Earnings Call

  • ACCESSWIRE5 months ago

    Affimed N.V. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Affimed N.V. (NASDAQ: AFMD ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 20, 2018, at 8:30 AM Eastern Time. To listen ...